Rolipram and Its Optical Isomers, Phosphodiesterase 4 Inhibitors, Attenuated the Scopolamine-Induced Impairments of Learning and Memory in Rats
Open Access
- 1 January 1997
- journal article
- Published by Elsevier in The Japanese Journal of Pharmacology
- Vol. 75 (3) , 275-281
- https://doi.org/10.1254/jjp.75.275
Abstract
We investigated the effects of (±)-rolipram, a phosphodiesterase (PDE) 4 inhibitor, and its isomers on scopolamine-induced deficits of learning and memory in rats using an 8-arm radial maze task and a passive avoidance task. 1) In the 8-arm radial maze task, (±)-rolipram (0.02-0.2 mg/kg, p.o.), (-)-rolipram (0.01-0.02 and 0.2-0.5 mg/kg, p.o.) and (+)-rolipram (20-50 mg/kg, p.o.) attenuated the scopolamine-induced deficits of spatial cognition. As for the minimum effective dose of each drug, (-)rolipram was 2 and 2000 times as potent as (±)-rolipram and (+)-rolipram, respectively. (-)-Rolipram produced a biphasic dose-response and (±)-rolipram produced a broad dose-response. 2) (±)-Rolipram and its isomers also attenuated the scopolamine-induced deficits in the passive avoidance response. Also for the minimum effective dose, (-)-rolipram (0.01 0.02 mg/kg) was 2 and 200 times as potent as (±)rolipram (0.02-0.1 mg/kg) and (+)-rolipram (2 mg/kg). 3) The behaviorally effective doses of (±)rolipram and its isomers also enhanced the oxotremorine-induced tremors in mice. Comparing these racemic isomers, (-) and (±)-rolipram have more potent effects than (+)-rolipram on scopolamine-induced deficits in the 8-arm radial maze task and passive avoidance task. Especially (±)-rolipram has a wide dose range in these behavioral study. These results suggest that the ameliorating effects of rolipram might result from the indirect potentiation of various transmitters including cholinergic and noradrenergic systems by an increase in cAMP with the inhibition of PDE4.Keywords
This publication has 28 references indexed in Scilit:
- Discriminative stimulus properties of the stereoisomers of the phosphodiesterase inhibitor rolipramPharmacology Biochemistry and Behavior, 1995
- High potassium and cyclic AMP analog promote neuronal survival of basal forebrain cholinergic neurons in culture from postnatal 2-week-old ratsDevelopmental Brain Research, 1994
- The Pharmacological Profile of (–)Deprenyl (Selegiline) and its Relevance for Humans: A Personal ViewBasic & Clinical Pharmacology & Toxicology, 1992
- Spatial memory deficits in aged rats: contributions of monoaminergic systemsBrain Research, 1990
- Dysbalance of neuronal second messenger function in the aetiology of affective disorders: A pathophysiological concept hypothesising defects beyond first messenger receptorsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1989
- CHOLINESTERASE INHIBITOR THERAPY FOR ALZHEIMER DEMENTIAAlzheimer Disease & Associated Disorders, 1988
- Scopolamine-disruption of radial arm maze performance: modification by noradrenergic depletionBrain Research, 1987
- Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer TypeNew England Journal of Medicine, 1986
- Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5Nature, 1986
- Acetylcholine and choline levels in post-mortem human brain tissue: Preliminary observations in Alzheimer's diseaseLife Sciences, 1980